Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 510.9% in April

Protara Therapeutics, Inc. (NASDAQ:TARA) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 398,300 shares, an increase of 510.9% from the March 31st total of 65,200 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 250,200 shares, the days-to-cover ratio is currently 1.6 days.

Analyst Ratings Changes

TARA has been the subject of a number of analyst reports. Oppenheimer boosted their price target on Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 8th.

Protara Therapeutics Price Performance

TARA traded down $0.12 on Friday, reaching $2.93. The company’s stock had a trading volume of 255,029 shares, compared to its average volume of 623,671. The stock has a market cap of $33.43 million, a price-to-earnings ratio of -0.82 and a beta of 1.71. Protara Therapeutics has a 1 year low of $1.04 and a 1 year high of $5.24. The business’s 50 day moving average is $3.72 and its 200 day moving average is $2.50.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.13. As a group, research analysts forecast that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.